Thromb Haemost 2008; 99(06): 1129-1131
DOI: 10.1160/TH08-03-0130
Letters to the Editor
Schattauer GmbH

PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: A meta-analysis of 19 studies comprising 3,003 patients

Marilena Crescente
1   Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy
,
Augusto Di Castelnuovo
1   Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy
,
Licia Iacoviello
1   Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy
,
Giovanni de Gaetano
1   Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy
,
Chiara Cerletti
1   Research Laboratories, “John Paul II” Centre for High Technology Research and Education in Biomedical Sciences, Catholic University, Campobasso, Italy
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 04. März 2008

Accepted after minor revision 09. April 2008

Publikationsdatum:
28. November 2017 (online)

 

 
  • References

  • 1 Crescente M, Di Castelnuovo A, Iacoviello L. et al. Response variability to aspirin as assessed by the platelet function analyzer (PFA)-100. A systematic review. Thromb Haemost 2008; 99: 14-26.
  • 2 Reny JL, de Moerloose P, Dauzat M. et al. Use of the PFA-100 trade mark closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis. J Thromb Haemost 2008; 6: 444-450.
  • 3 Krasopoulos G, Brister SJ, Beattie WS. et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. Br Med J 2008; 336: 195-198.
  • 4 Snoep JD, Hovens MM, Eikenboom JC. et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007; 167: 1593-1599.
  • 5 Di Castelnuovo A, Soccio M, Iacoviello L. et al. “The C242 T polymorphism of the p22phox component of NAD(P)H oxidase and vascular risk. Two case-control studies and meta-analyses. Thromb Haemost 2008; 99: 594-601.